, /PRNewswire/ -- the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with , a global pharmaceutical company during . The entities will work to enhance position as leading global hub for healthcare, life science and innovation. Leveraging the Emirate's unique capabilities and future-forward data services as well as Pfizer's global capabilities, the parties seek to advance research through the generation and analysis of real-world data (RWD) initially focusing on Sickle Cell Disease (SCD) and expanding to other disease areas for the benefit of patients.
In the presence of H.E. , Chairman of DoH, the MoU was signed by Dr , the Executive Director of the Research and Innovation Centre at DoH, and , Pfizer's Gulf Cluster Lead.
said: "The collaboration between the DoH and Pfizer represents a significant step towards harnessing real-world data in the region and better understanding patient populations from the vast available data in . By partnering with Pfizer on real-world data, we aim to drive advancements in healthcare prediction, prevention, personalised treatment and access, not only benefiting healthcare professionals and patients in , but also contributing to the improvement of care for patients globally." "It is a significant moment for Pfizer Gulf as we sign this Memorandum of Understanding with the Department of Health.
This collaboration is not just a testament to our shared vision but also a strategic step towards enhancing h.
